Advaxis Stumbles Further As Amgen Exits Early-Stage Cancer Immunotherapy Pact - Scrip

Advaxis Stumbles Further As Amgen Exits Early-Stage Cancer Immunotherapy Pact  Scrip

Troubled by a clinical hold for another program, Advaxis now regains all rights to ADXS-NEO, a personalized immunotherapy in Phase I for cervical and ...

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2PGkThL